Skip to main content
SpringerLink
Log in

Dermatologische topische und Systemtherapie in der Schwangerschaft

Dermatological topical and systemic therapy during pregnancy

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Während der Schwangerschaft ist ein erfolgreiches und sicheres therapeutisches Management der Patienten zur Verringerung der Krankheitslast möglich. Meist reicht eine topische Therapie, ggf. begleitet von einer Basistherapie. Darüber hinaus können Systemtherapien z. B. bei Autoimmunerkrankungen oder Psoriasis durchaus sicher eingesetzt werden. Hier gilt es, auch bei geplanten Schwangerschaften frühzeitig Medikamente abzusetzen, zu reduzieren, mögliche alternative Therapien zu besprechen bzw. ein frühes Monitoring zu starten. Zu bedenken ist immer, dass Medikamente in möglichst geringer Dosis (ohne Okklusion bei Lokaltherapien) und kurzzeitig (Ausnahme: Autoimmun- oder maligne Erkrankungen) anzuwenden sind. Eine interdisziplinäre Zusammenarbeit zwischen Gynäkologen, Rheumatologen, Internisten und Dermatologen sowie Pharmazeuten ist unabdingbar.

Abstract

During pregnancy, a successful and safe therapeutic management of patients is possible to lower the burden of disease. Often topical therapy in combination with intensive basic skin care is sufficient. Drug therapies may also be used, most often for systemic diseases such as autoimmune diseases or psoriasis. An early change in therapy is also key during planned pregnancies so that treatments can be switched, adjusted, reduced or closely monitored. Another point to consider is to keep drug dosing as low as possible (without occlusion in local therapy) or short termed (with the exception of autoimmune or malignant diseases). An interdisciplinary collaboration between obstetrics and gynecology/rheumatology/internal medicine/dermatology as well as pharmacologists is of utmost importance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ahmed AR, Gurcan HM (2011) Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol 25:1073–1079

    Article  CAS  PubMed  Google Scholar 

  2. Andrulonis R, Ferris LK (2012) Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 11:1240

    PubMed  Google Scholar 

  3. Brabin BJ, Eggelte TA, Parise M et al (2004) Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes. Drug Saf 27:633–648

    Article  CAS  PubMed  Google Scholar 

  4. Braunstein I (2013) Werth V Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther 26:354–363

    Article  PubMed  Google Scholar 

  5. Carmichael SL, Shaw GM, Ma C et al (2007) Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197:585–587

    Article  PubMed  Google Scholar 

  6. Chang Z, Spong CY, Jesus AA et al (2014) Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol 66:3227–3232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cheent K, Nolan J, Shariq S et al (2010) Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis 4:603–605

    Article  PubMed  Google Scholar 

  8. Chi CC, Wang SH, Wojnarowska F et al (2015) Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. doi:10.1002/14651858.cd007346.pub2

    Google Scholar 

  9. Choi JS, Koren G, Nulman I (2013) Pregnancy and isotretinoin therapy. CMAJ 185:411–413

    Article  PubMed  PubMed Central  Google Scholar 

  10. Clowse ME, Magder L, Petri M (2005) Cyclophosphamide for lupus during pregnancy. Lupus 14:593–597

    Article  CAS  PubMed  Google Scholar 

  11. Fotiadou C, Lazaridou E, Sotiriou E et al (2012) Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 6:105–107

    Article  PubMed  PubMed Central  Google Scholar 

  12. Garner P, Gulmezoglu AM (2006) Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev. doi:10.1002/14651858.cd000169.pub2

    Google Scholar 

  13. Gilboa SM, Ailes EC, Rai RP et al (2014) Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf 13:1667–1698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gotestam SC, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795–810

    Article  Google Scholar 

  15. Grunewald S, Jank A (2015) New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 13:277–289

    PubMed  Google Scholar 

  16. Hviid A, Molgaard-Nielsen D (2011) Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 183:796–804

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hyrich KL (2014) Verstappen SM Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 53:1377–1385

    Article  CAS  Google Scholar 

  18. Ke AB, Rostami-Hodjegan A, Zhao P et al (2014) Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol 54:53–69

    Article  CAS  PubMed  Google Scholar 

  19. Lannes G, Elias FR, Cunha B et al (2011) Successful pregnancy after cyclophosphamide therapy for lupus nephritis. Arch Gynecol Obstet 283(Suppl 1):61–65

    Article  PubMed  Google Scholar 

  20. Levy RA, de Jesus GR, de Jesus NR et al (2016) Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 15:955–963

    Article  PubMed  Google Scholar 

  21. Li J, Chen Y, Liu C et al (2013) Intravenous immunoglobulin treatment for repeated IVF/ICSI failure and unexplained infertility: a systematic review and a meta-analysis. Am J Reprod Immunol 70:434–447

    Article  CAS  PubMed  Google Scholar 

  22. Maleka A, Enblad G, Sjors G et al (2013) Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol 31:E192–E193

    Article  PubMed  Google Scholar 

  23. Martinez Lopez JA, Loza E, Carmona L (2009) Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 27:678–684

    CAS  PubMed  Google Scholar 

  24. Muallem MM, Rubeiz NG (2006) Physiological and biological skin changes in pregnancy. Clin Dermatol 24:80–83

    Article  PubMed  Google Scholar 

  25. Mukhopadhyay A, DasGupta S, Kanti RU et al (2014) Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci 184(1):183–188. doi:10.1007/s11845-014-1084-5

    Article  PubMed  Google Scholar 

  26. Murase JE, Heller MM, Butler DC (2014) Safety of dermatologic medications in pregnancy and lactation: part I. pregnancy. J Am Acad Dermatol 70:401–414

    Article  PubMed  Google Scholar 

  27. Mylonas I (2011) Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Arch Gynecol Obstet 283:7–18

    Article  CAS  PubMed  Google Scholar 

  28. Ostensen M (2014) Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci 1317:32–38

    Article  PubMed  Google Scholar 

  29. Pasternak B, Hviid A (2010) Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304:859–866

    Article  CAS  PubMed  Google Scholar 

  30. Perez-Aytes A, Ledo A, Boso V et al (2008) In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 146A:1–7

    Article  PubMed  Google Scholar 

  31. Pilmis B, Jullien V, Sobel J et al (2015) Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother 70:14–22

    Article  CAS  PubMed  Google Scholar 

  32. Poulet FM, Wolf JJ, Herzyk DJ et al (2016) An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors. Birth Defects Res B Dev Reprod Toxicol 107:108–119

    Article  CAS  PubMed  Google Scholar 

  33. Routsias JG, Kyriakidis NC, Friedman DM et al (2011) Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum 63:2783–2789

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Saulnier PJ, Piguel X, Perault-Pochat MC et al (2010) Hypoglycaemic seizure and neonatal acute adrenal insufficiency after maternal exposure to prednisone during pregnancy: a case report. Eur J Pediatr 169:763–765

    Article  PubMed  Google Scholar 

  35. Sheeran C, Nicolopoulos J (2014) Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol 55:235–236

    Article  PubMed  Google Scholar 

  36. Sperber K, Hom C, Chao CP et al (2009) Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 7:9

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tracy TS, Venkataramanan R, Glover DD et al (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 192:633–639

    Article  CAS  PubMed  Google Scholar 

  38. Treudler R, Kauer F, Simon JC (2007) Striking effect of the IL-1 receptor antagonist anakinra in chronic urticarial rash with polyclonal increase in IgA and IgG. Acta Derm Venereol 87:280–281

    PubMed  Google Scholar 

  39. Yazdani BP, Matok I, Garcia BF et al (2012) A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 33:265–268

    Article  Google Scholar 

  40. Young GL, Jewell D (2001) Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev. doi:10.1002/14651858.cd000225

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig AöR, Ph.-Rosenthal-Str. 23, 04103, Leipzig, Deutschland

    S. Grunewald

  2. Hautklinik und Poliklinik, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland

    P. Staubach

Authors
  1. S. Grunewald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Staubach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Grunewald.

Ethics declarations

Interessenkonflikt

S. Grunewald und P. Staubach geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grunewald, S., Staubach, P. Dermatologische topische und Systemtherapie in der Schwangerschaft. Hautarzt 68, 127–135 (2017). https://doi.org/10.1007/s00105-016-3921-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-016-3921-0

Schlüsselwörter

Keywords

Search

Navigation